AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36203788
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) morphine (0.01 mg/kg/h)
Trial: 35323474
Drug: Brown seaweed
RxNorm normalized name: seaweed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brown seaweed extract (500 mg/d)
Trial: 32332648
Drug: Transvaginal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transvaginal electrical stimulation (TVES) for 3 times with EMG-triggered neuromuscular stimulation twice
Trial: 34032715
Drug: Other chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapeutic agents
Trial: 36871476
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy alone
Trial: 33694253
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of nanoencapsulated eugenol (NE)
Trial: 33461852
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized JC pollen extract
Trial: 33567016
Drug: Coconut water-based
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coconut water-based solution (G1)
Trial: 35093409
Drug: Tocovid SupraBio
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tocovid SupraBio 200mg and pentoxifylline 400mg orally twice daily for one year
Trial: 34577869
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity extracorporeal shock wave therapy (LiESWT) with 0.25 mJ/mm2 intensity, 3000 pulses, and 3 pulses/s, once weekly for 4 weeks
Trial: 34577869
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity extracorporeal shock wave therapy (LiESWT) with 0.25 mJ/mm2 intensity, 3000 pulses, and 3 pulses/s, once weekly for 8 weeks
Trial: 34577869
Drug: Sham LiESWT
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham LiESWT treatment without energy transmission
Trial: 33493544
Drug: Daily Undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Undulating Programming (DUP)
Trial: 34965026
Drug: Polyvalent mechanical
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent mechanical bacterial lysate (PMBL) administered sublingually for 12 weeks
Trial: 32421218
Drug: Ad‐HMN patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad‐HMN patch
Trial: 32421218
Drug: Ad‐LMN patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad‐LMN patch
Trial: 32205677
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (EX) - combination of heavy and explosive strength and sprint exercises for 20 weeks
Trial: 616191717
Drug: Salt-soda solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt-soda solution (SSS)
Trial: 86216967
Drug: Pre-operative intravenous
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intravenous infusion cholangiography and selective operative cholangiography (group 2)
Trial: 33831803
Drug: Laughter yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laughter yoga (30 min, 16 sessions, twice-weekly)
Trial: 33647748
Drug: Porous Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous Plasma Spray (VP) coated tibial component
Trial: 35815916
Drug: Isotretinoin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (20 mg daily) and topical tacrolimus (0.1% BD)
Trial: 35815916
Drug: Finasteride (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (2.5 mg daily) and topical tacrolimus (0.1% BD)
Trial: 34872140
Drug: Infertility counseling
RxNorm normalized name: Tests for fertility disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infertility counseling for 6 sessions (45 minutes each, twice a week)
Trial: 33278020
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg daily for 5 days
Trial: 33278020
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg daily for 5 days
Trial: 32564614
Drug: Tiered tax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiered tax (<5 g of added sugar/8 oz: no tax; 5-20 g/8 oz: $0.01/oz; >20 g/8 oz: $0.02/oz)
Trial: 34543323
Drug: Steroid intake,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid intake, ileus, acute kidney injury (AKI), metabolic acidosis, hypocalcemia
Trial: 35861176
Drug: Non-protein calorie
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-protein calorie supplements (280 kcal/day for 6 months)
Trial: 34598781
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose methylprednisolone (MP)
Trial: 34598781
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose methylprednisolone (MP) administered at home
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab (2 prefilled syringes of 120 mg)
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab with conventional preventive therapy
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab as initial preventive therapy
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab therapy add-on conventional preventive therapy
Trial: 36209047
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of galcanezumab initial therapy
Trial: 34407846
Drug: Supplementation dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation dose of 3 g of vitamin C per day for 96 h
Trial: 34407846
Drug: Pharmacological dose
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological dose of 10 g of vitamin C per day for 96 h
Trial: 33861768
Drug: Maternal praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal praziquantel (PZQ) treatment
Trial: 34702443
Drug: Calcitriol 0.5
RxNorm normalized name: CALCITRIOL 0.5MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.5 μg per os twice daily for three days before surgery
Trial: 36265502
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for 17 cycles)
Trial: 32044505
Drug: PGE1 treatment
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 treatment (intravenous injection)
Trial: 36214628
Drug: Therapist-supported acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-supported acceptance and commitment therapy-based bibliotherapy (bi-weekly therapist support)
Trial: 35650554
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (load dose 0.5 μg kg−1 over 10 min, followed by maintenance dose 0.2 μg kg−1 h−1)
Trial: 34916855
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) administered 2 weeks after fertilization for 6 months
Trial: 34916855
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 2 weeks after fertilization for 6 months
Trial: 34384282
Drug: Oral maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral maraviroc (MVC) 300 mg dosed orally
Trial: 34384282
Drug: MVC 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC 1% gel dosed rectally
Trial: 34384282
Drug: MVC 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC 1% gel dosed vaginally
Trial: 36200403
Drug: Mailed brochure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed brochure about BZRA risks and information about a free, online cognitive behavioral therapy for insomnia (CBTI) program (Arm 1)
Trial: 36200403
Drug: Mailed brochure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed brochure without insomnia treatment information (Arm 3)
Trial: 35931131
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with uterosacral suspension
Trial: 33861375
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day (low dose)
Trial: 33861375
Drug: Prednisolone 2
RxNorm normalized name: prednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 2 mg/kg/day (standard dose)
Trial: 34724640
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) algorithms - Random Forest Classifier (RFC)
Trial: 34716753
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 μg/kg/min as a continuous 24‐h intravenous infusion administered once monthly for 1 year)
Trial: 35472247
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention (counselling intervention including drug information and answering queries)
Trial: 33856395
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1 g every 6 hours for 48 hours)
Trial: 33856395
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g every 6 hours for 48 hours)
Trial: 34074289
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 12 weeks
Trial: 33208583
Drug: Goreisan for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan for 3 months (Group G)
Trial: 33208583
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Group N)
Trial: 33208583
Drug: Goreisan for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan for 3 months (Group G) in high-risk patients
Trial: 33208583
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Group N) in high-risk patients
Trial: 36443869
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive behavioral therapy for insomnia (gCBT-I)
Trial: 34588952
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day istradefylline
Trial: 35448974
Drug: Resistance Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Training (RT) for 12 weeks, coupled with Behavioral Activation techniques, meeting twice/week.
Trial: 35448974
Drug: Attention-control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-control group (Health, Wellness, and Education; HWE) for 12 weeks, meeting twice/week.
Trial: 33634552
Drug: Combination oral
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral clindamycin plus rifampicin (C + R)
Trial: 33634552
Drug: Oral clindamycin
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clindamycin monotherapy (CM)
Trial: 33710319
Drug: β-blocker prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker prescription
Trial: 35887551
Drug: Iloprost (ILO)
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost (ILO) inhalation
Trial: 32533427
Drug: Insulin loading
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin loading procedure
Trial: 33797658
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis of analgesics (meloxicam, celecoxib, rofecoxib)
Trial: 34455503
Drug: Tilted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilted group implants (2 anterior axial and 2 posterior distally inclined implants)
Trial: 34455503
Drug: Axial group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axial group implants (2 implants in the interforaminal area and 2 in the molar area)
Trial: 33326656
Drug: Withdrawal combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal combined with preventive medication (W+P)
Trial: 33326656
Drug: Withdrawal with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal with optional preventive medication (W)
Trial: 33326656
Drug: Preventive medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive medication without withdrawal (P)
Trial: 33529350
Drug: Sunscreens and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreens and cosmetic formulations containing ascorbyl tetraisopalmitate and rice peptides
Trial: 35428613
Drug: Co-amoxiclav 400/57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 400/57 suspension
Trial: 32252680
Drug: Concurrent EP
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent EP (etoposide + cisplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Trial: 32252680
Drug: Concurrent PC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent PC (paclitaxel + carboplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Trial: 35945745
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with intravenous ibuprofen (10 mg/kg) administered once within 6 hours after birth
Trial: 35945745
Drug: Non-prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prophylactic treatment (non-PT)
Trial: 35945745
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with intravenous ibuprofen (10 mg/kg)
Trial: 34911530
Drug: Conventional non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-surgical therapy (CNST)
Trial: 33604941
Drug: Twice-daily regimen
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily regimen (UFT 300 mg/m2 per day, LV 50 mg per day)
Trial: 33604941
Drug: Three-times-daily regimen
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily regimen (UFT 300 mg/m2 per day, LV 75 mg per day)
Trial: 35927627
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (RIC) + best medical treatment (BMT)
Trial: 34324933
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 μg.kg-1) followed by propofol (1 mg.kg-1) after 1 minute
Trial: 34324933
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 μg.kg-1) followed by propofol (2 mg.kg-1) after 2 minutes
Trial: 34324933
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (1 min and 2 min with varying doses of propofol)
Trial: 32167611
Drug: Full-energy enteral
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-energy enteral feeding starting at 75% of daily energy expenditure, increasing to 90%-100%.
Trial: 32167611
Drug: Hypocaloric enteral
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric enteral feeding starting with 30% of daily energy expenditure, reaching 75% within 7 days.
Trial: 35176136
Drug: Both Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both Bevacizumab and Cetuximab plus chemotherapy
Trial: 34706141
Drug: Sunitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib treatment duration in immediate arm
Trial: 34706141
Drug: Sunitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib treatment duration in deferred arm
Trial: 34545166
Drug: Treatment-as-usual comparison
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual comparison group
Trial: 36420043
Drug: infant standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infant standard therapy
Trial: 35448895
Drug: Intracavernosal incobotulinumtoxinA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal incobotulinumtoxinA (Xeomin®) 100 U as an add-on therapy
Trial: 33529664
Drug: Apixaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (2.5 mg dose)
Trial: 34986793
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received CFNB and sciatic nerve block with 0.16% levobupivacaine and 6 mg indigo carmine at 6 ml/h
Trial: 32970172
Drug: β‐lactam antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐lactam antibiotic treatment for less than seven days
Trial: 35583488
Drug: Anabolic-androgenic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic-androgenic steroids (AAS)
Trial: 33627069
Drug: FindMyApps intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FindMyApps intervention (tablet computer and FindMyApps)
Trial: 33627069
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (control arm - tablet computer)
Trial: 35215431
Drug: 50% taro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% taro flour + 50% wheat flour + probiotic L. plantarum IS‐10506
Trial: 32719251
Drug: Ayurvedic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic preparation Yashtimadhu in addition to conventional treatment
Trial: 32719251
Drug: Conventional mucositis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional mucositis treatment
Trial: 32719251
Drug: Honey for
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey for local application and oral intake in addition to routine conventional treatment
Trial: 33621332
Drug: Meditation and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meditation and Exercise Treatment (MedExT)
Trial: 34712343
Drug: Harpagophytum procumbens
RxNorm normalized name: Harpagophytum procumbens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harpagophytum procumbens (Teltonal) 2 tablets (2*480 mg) daily for one month
Trial: 34712343
Drug: meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 15 mg daily for ten days
Trial: 34010183
Drug: ACEI/ARB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB treatment after PCI
Trial: 34010183
Drug: ACEI/ARB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB treatment after CABG
Trial: 34010183
Drug: No ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACEI/ARB treatment after PCI
Trial: 34010183
Drug: No ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACEI/ARB treatment after CABG
Trial: 34010183
Drug: No ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACEI/ARB treatment
Trial: 34949637
Drug: Two-stage consent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage consent pathway (oral assent followed by informed written consent)
Trial: 36000981
Drug: ACT-1014-6470 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-1014-6470 (60 mg)
Trial: 34536664
Drug: Cannabidiol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (0.25 ml, 5% cannabidiol, 12.5 mg cannabidiol)
Trial: 34174349
Drug: Mock (control)
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock (control) treatment
Trial: 33095633
Drug: Certification methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certification methods for quantum state preparation and measurement devices
Trial: 33879769
Drug: SEP-363856 50
RxNorm normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-363856 50 mg